Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Supernus Pharm (NQ: SUPN )

29.32 +0.45 (+1.56%)
Streaming Delayed Price Updated: 11:21 AM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 56,062
Open 28.67
Bid (Size) 29.30 (2)
Ask (Size) 29.38 (1)
Prev. Close 28.87
Today's Range 28.67 - 29.50
52wk Range 21.99 - 39.09
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
+5.73%
+5.73%
1 Month
-16.59%
-16.59%
3 Month
+6.54%
+6.54%
6 Month
+23.30%
+23.30%
1 Year
-21.23%
-21.23%

More News

Read More
Supernus Provides Regulatory Update for SPN-830
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Biotechnology And Healthcare, A Bit Of A Lull
Via Talk Markets
Recap: Supernus Pharmaceuticals Q4 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
Supernus Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Supernus to Participate in Two Upcoming Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
Via InvestorPlace
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
Via Benzinga
Exposures Product Safety
Supernus Announces Third Quarter 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For November 8, 2023
Via Benzinga
Supernus to Participate in the Jefferies London Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.